CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that its lead product candidate, tivozanib, has been selected as one of Windhover’s “2011 Top 10 Oncology Projects to Watch.” Tivozanib is a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, currently being evaluated in a global Phase 3 clinical trial, TIVO-1, comparing tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC).
